Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.72 USD
-0.10 (-5.49%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $1.73 +0.01 (0.58%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
Lexicon Pharmaceuticals, Inc. [LXRX]
Reports for Purchase
Showing records 161 - 180 ( 393 total )
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
February and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Best Ideas List-Updates
Provider: WEDBUSH SECURITIES INC.
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2017 Preview: Our Top Picks, and Key Data Readouts and Launches Up Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
January and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2017 Biopharmaceutical Industry Outlook
Provider: Rodman & Renshaw, Co.
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2017 Biopharmaceutical Industry Outlook
Provider: H.C. Wainwright & Co., Inc.
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We See Both Pivotal T1D Trials Supporting Potential 2018 FDA Review
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We See Both Pivotal T1D Trials Supporting Potential 2018 FDA Review -- Possible Hint in Q1 Could be Catalyst; Reiterate OUTPERFORM and $33 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Revised Best Ideas List for 2017
Provider: WEDBUSH SECURITIES INC.
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Best Ideas List for 2017This report contains brief updates on the following: ARDX, BC, BLDR, CVA, FINL, FIS, IPG, LULU, LXRX, MASI, NRZ, PFPT, PB, PHM, QUOT, SHAK, TRVN, ZNGA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: LURIA G
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
JDRF T1D Phase 2 HbA1c Primary Endpoint Showed Positive Trend, Secondary EPs Significant Plus Excellent Safety; Reiterate OUTPERFORM and $33 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
December and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
November and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q16: A Busy Winter With Two Sota Trial Readouts and Potential Telotristat Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Update: Lots of Cash and Multiple Clinical and Regulatory Catalysts on the Horizon; Reiterate
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L